Thematics Asset Management Makes New Investment in IQVIA Holdings Inc. (NYSE:IQV)

Thematics Asset Management bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 388 shares of the medical research company’s stock, valued at approximately $76,000.

A number of other large investors also recently modified their holdings of IQV. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at about $33,000. GKV Capital Management Co. Inc. purchased a new position in IQVIA in the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new position in IQVIA in the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. raised its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the last quarter. Finally, Versant Capital Management Inc lifted its holdings in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after buying an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research analyst reports. Mizuho cut their price objective on IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a research report on Wednesday, April 9th. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Barclays reissued an “equal weight” rating and issued a $170.00 target price (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Finally, Truist Financial reduced their target price on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a report on Thursday, April 10th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $241.50.

IQVIA Price Performance

Shares of IQV stock opened at $143.66 on Monday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $25.33 billion, a P/E ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46. The company’s 50-day simple moving average is $176.42 and its two-hundred day simple moving average is $196.40. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.